Home » Stocks » TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. (TCON)

Stock Price: $1.87 USD 0.06 (3.31%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $1.84 -0.03 (-1.60%) Aug 7, 7:51 PM

Stock Price Chart

Key Info

Market Cap 10.29M
Revenue (ttm) n/a
Net Income (ttm) -17.61M
Shares Out 8.50M
EPS (ttm) -5.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.87
Previous Close $1.81
Change ($) 0.06
Change (%) 3.31%
Day's Open 1.78
Day's Range 1.76 - 1.90
Day's Volume 189,061
52-Week Range 0.95 - 6.10

More Stats

Market Cap 10.29M
Enterprise Value 339,729
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 8.50M
Float 4.71M
EPS (basic) -4.35
EPS (diluted) -5.44
FCF / Share -3.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 72,958
Short Ratio 0.50
Short % of Float 2.23%
Beta 1.94
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.87
Revenue n/a
Operating Income -17.09M
Net Income -17.61M
Free Cash Flow -19.97M
Net Cash 9.95M
Net Cash / Share 1.81
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -47.60%
ROE -221.53%
ROIC 441.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 1
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$3.50*
(87.17% upside)
Low
3.00
Current: $1.87
High
4.00
Target: 3.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue-3.008.763.457.903.60--
Revenue Growth--65.73%153.84%-56.36%119.68%---
Gross Profit-3.008.763.457.903.60--
Operating Income-22.30-34.74-18.21-25.98-23.47-6.18-7.56-5.23
Net Income-22.67-34.96-19.10-27.01-24.41-6.81-7.71-4.93
Shares Outstanding3.032.691.681.271.110.160.160.16
Earnings Per Share-7.47-12.97-11.37-21.30-22.00-44.00-49.30-31.90
Operating Cash Flow-23.65-30.78-13.24-27.15-19.161.76-6.67-5.43
Capital Expenditures---0.04--0.13-0.07-0.01-0.01
Free Cash Flow-23.65-30.78-13.28-27.15-19.291.69-6.68-5.44
Cash & Equivalents16.4139.1034.4744.4152.1635.002.280.00
Total Debt5.346.437.448.318.848.932.44-
Net Cash / Debt11.0732.6827.0336.1043.3126.07-0.170.00
Assets18.1240.6536.1345.7353.5238.172.42-
Liabilities15.4219.2119.1417.3922.5470.3527.76-
Book Value2.7021.4416.9928.3430.98-32.17-25.34-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name TRACON Pharmaceuticals, Inc.
Country United States
Employees 19
CEO Charles P. Theuer

Stock Information

Ticker Symbol TCON
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TCON
IPO Date January 30, 2015

Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.